Brexanalone

Taken from the March/April 2019 issue of The Women’s Health Activist Newsletter. Last November, the Food and Drug Administration’s (FDA) Reproductive Health Drugs Advisory Committee voted overwhelmingly in favor of brexanolone, a first-of-its-kind treatment for postpartum depression (PPD).[1] [2] We…